tiprankstipranks
Trending News
More News >
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
US Market
Advertisement

Supernus Pharmaceuticals (SUPN) Ownership - Who Owns Supernus Pharmaceuticals?

Compare
509 Followers

Supernus Pharmaceuticals (SUPN) Ownership Overview

4.21%34.94%30.72%28.09%2.04%
30.72% Other Institutional Investors
28.09% ETFs
2.04% Public Companies and
Individual Investors
The ownership structure of Supernus Pharmaceuticals (SUPN) stock is a mix of institutional, retail, and individual investors. Approximately 93.75% of the company’s stock is owned by Institutional Investors, 4.21% is owned by Insiders, and 2.04% is owned by Public Companies and Individual Investors.
The ownership structure of Supernus Pharmaceuticals (SUPN) stock is a mix of institutional, retail, and individual investors. Approximately 65.66% of the company’s stock is owned by Institutional Investors, 4.21% is owned by Insiders, and 28.09% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 18, 2025
xxxxxxxxxxxxx
$315133
Aug 08, 2025
xxxxxxxxxxxxx
$5883360
Feb 05, 2025
xxxxxxxxxxxxx
$376237
Jan 29, 2025
xxxxxxxxxxxxx
$129676

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$330329
Jun 30, 2025
xxxxxxxxxxxxx
$376695
Jun 30, 2025
xxxxxxxxxxxxx
$1024526
Jun 30, 2025
xxxxxxxxxxxxx
$24364203

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
6,174,069Institution11.01%263,571,006
5,192,991Institution9.26%221,688,786
4,712,429Institution8.40%201,173,594
4,078,684Institution7.27%174,119,020
2,075,533Insider3.70%88,604,504
1,715,718Institution3.06%73,244,001
998,422Institution1.78%42,622,635
995,694Institution1.78%42,506,177
890,981Institution1.59%38,035,979
772,976Institution1.38%32,998,345

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
4,712,429Institution8.40%201,173,594
4,078,684Institution7.27%174,119,020
1,715,718Institution3.06%73,244,001
995,694Institution1.78%42,506,177
634,155Institution1.13%27,072,077
570,029Institution1.02%24,334,538
554,551Institution0.99%23,673,782
395,203Institution0.70%16,871,216
385,737Institution0.69%16,467,113
358,847Institution0.64%15,319,178

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,332,742Institution5.94%142,274,756
1,684,308Institution3.00%59,119,211
1,290,030Institution2.30%45,280,053
1,286,688Institution2.29%54,928,711
832,127Institution1.48%29,207,658
602,536Institution1.07%21,149,014
488,528Institution0.87%20,601,226
474,809Institution0.85%20,022,696
435,047Institution0.78%18,572,156
333,360Institution0.59%14,231,138

FAQ

Who Owns Supernus Pharmaceuticals (SUPN)?
According to the latest TipRanks data, approximately 30.72% of the company's stock is held by institutional investors, 4.21% is held by insiders, and 2.04% is held by retail investors.
    What percentage of Supernus Pharmaceuticals (SUPN) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 30.72% of Supernus Pharmaceuticals (SUPN) stock is held by institutional investors.
      What percentage of Supernus Pharmaceuticals (SUPN) stock is held by retail investors?
      According to the latest TipRanks data, approximately 2.04% of Supernus Pharmaceuticals (SUPN) stock is held by retail investors.
        Who owns the most shares of Supernus Pharmaceuticals (SUPN)?
        iShares owns the most shares of Supernus Pharmaceuticals (SUPN).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis